Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biotime Inc receives FDA premarket notification clearance for Premvia(tm) 510(k)


Tuesday, 12 Aug 2014 09:00am EDT 

Biotime Inc:Received notice from FDA's Center for Devices and Radiologic Health that Premvia (tm) has been cleared for marketing as Class II medical device.Premvia (tm)( )is first FDA-cleared member of BioTime's HyStem ( (reg) )family of hydrogels, which are designed to mimic the natural structures of human body's extracellular matrix.According to FDA clearance, product is indicated for management of wounds including: partial thickness, full-thickness, tunneling wounds, pressure ulcers, venous ulcers, diabetic ulcers.It also includes chronic vascular ulcers, donor skin graft sites, post-Moh's surgery, post-laser surgery, podiatric wounds, wound dehiscence, abrasions, lacerations, second degree burns, skin tears and draining wounds. 

Company Quote

3.33
-0.13 -3.76%
19 Dec 2014